In vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales Producing blaKPC or blaNDM-Reference-Cited by-同舟云学术

In vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales Producing blaKPC or blaNDM

Published:2023-05 Issue: Volume:Volume 16 Page:3171-3182
ISSN:1178-6973
Container-title:Infection and Drug Resistance
language:en
Short-container-title:IDR

Author:

Kuai Junyang,Zhang Yawei,Lu Binghuai^ORCID,Chen Hongbin,Zhang Yulin,Li Henan,Wang Yuanyuan,Wang Qi,Wang Hui,Wang Xiaojuan

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases,Pharmacology

Reference33 articles.

1. Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review

2. Phenotypic and Genotypic Characterization of Carbapenem-resistantEnterobacteriaceae: Data From a Longitudinal Large-scale CRE Study in China (2012–2016)

3. Antibiotic Heteroresistance in Klebsiella pneumoniae

4. Effectiveness of a double-carbapenem combinations against carbapenem-resistant Gram-negative bacteria

5. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Vitro Synergistic Effect of Colistin with Fosfomycin Against Carbapenem-Resistant Klebsiella pneumoniae;Cureus;2024-08-06

2. Endophthalmitis therapy revolution: Proof of concept based on in vivo evaluation of maleic acid modified chitosan;Journal of Drug Delivery Science and Technology;2024-06

3. In vitro and in vivo activity of ceftazidime/avibactam and aztreonam alone or in combination against mcr-9, serine- and metallo-β-lactamases–co-producing carbapenem-resistant Enterobacter cloacae complex;European Journal of Clinical Microbiology & Infectious Diseases;2024-05-03

4. Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and Pseudomonas aeruginosa;Antibiotics;2024-03-21

5. Reviewing novel treatment options for carbapenem-resistant Enterobacterales;Expert Review of Anti-infective Therapy;2024-01-10